High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer

European Journal of Cancer

Volumn 31, Issue 6, 1995, Pages 1009-1016

  Lejeune, F J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MELPHALAN; PARACETAMOL; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; HUMAN; LIMB PERFUSION; LIMB TUMOR; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; INTERFERON-GAMMA, RECOMBINANT; MELANOMA; MELPHALAN; MICE; MODELS, BIOLOGICAL; PERFUSION, REGIONAL; RECOMBINANT PROTEINS; SARCOMA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR;

EID: 0029034065     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(94)00512-5     Document Type: Article

References (57)

1. An endotoxin-induced serum factor that causes necrosis of tumours
2. Human tumor necrosis factor: production, purification and characterization
3. Molecular cloning of mouse tumor necrosis factor cDNA and its eukaryotic expression
4. Cloning and expression in E. coli of the cDNA for murine tumor necrosis factor
5. Tumor necrosis factor (TNF)
6. Cachectin and tumor necrosis factor as two sides of the same biological coin
7. Tumor Necrosis Factor: receptors and inhibitors
8. Recombinant human tumor necrosis factor administered as a 24 h intravenous infusion. A phase I and pharmacologic study
9. Phase I trial of recombinant human tumor necrosis factor
10. A phase I trial of recombinant human tumor necrosis factor in cancer patients
11. Phase I study of recombinant human tumor necrosis factor
12. Clinical pharmacology of recombinant human tumor necrois factor in patients with advanced cancer
13. A phase I trial of intravenously administered recombinant tumor necrosis factor alpha in cancer patients
14. Recombinant human tumor necrosis factor administered as a five day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism
15. High doses of rTNF-alpha in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
16. The pathophysiology of tumor necrosis factors
17. Human tumor xenografts treated with human TNF alone or in combination with interferon
18. Recombinant interferon gamma and its synergism with tumor necrosis factor in the human and mouse systems
19. The l-arginine-nitric oxide pathway
20. High serum levels of TNF-alpha after its administration for isolation perfusion of the limbs
21. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
22. Management of local recurrences, satellites and in transit metastases of the limbs with isolation perfusion
23. Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic in transit melanoma
24. Antitumor effect of recombinant human tumor necrosis factor alpha and its augmentation in vivo and in vivo
25. Isolated limb perfusion with tumor necrosis factorα and melphalan for fibrosarcoma in Brown Norway rats
26. Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon
27. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia
28. Heat potentitation of melphalan: studies on melphalan transport systems
29. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower-limb: technique and results
30. Systemic and hemodynamic effects of high-dose recombinant tumor necrosis factor alpha in isolation perfusion of the limbs for melanoma and malignant soft tissue tumors
31. Systemic release of soluble tumor necrosis factor alpha receptors (sTNFr) after isolated limb perfusion with high dose TNFα
32. A human tumor necrosis factor (TNF) α mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon
33. Regional isolated perfusion for melanoma of the extremities
34. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities
35. Limb salvage with high dose TNFalpha, interferon and melphalan isolated limb perfusion for unresectable soft tissue sarcomas of the limb
36. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan
37. Low-dose tumor necrosis factor-alpha and melphalan in hyperthermic isolated limb perfusion
38. Systemic toxicity and cytokine levels in patients undergoing isolated limb perfusion (ILP) with high dose TNF, IFNgamma and melphalan
39. The treatment of extensive limb soft tissue sarcoma by isolation perfusion with high dose r-Tumour necrosis factor alpha combined with melphalan
40. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNFα), melphalan and interferon-gamma (IFNγ). Dose-finding experience at the National Cancer Institute of Milan
41. The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results
42. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer
43. A phase I trail of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo
44. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high dose tumor necrosis factor alpha
45. Intravascular thrombocyte aggregation and erythrostasis are associated with necrosis in melanoma metastases after perfusion with a high dose of tumor necrosis factor alpha
46. Phenotype changes occurring in peripheral blood T lymphocytes from patients treated by high dose rTNFalpha in isolation limb perfusion
47. Immunotherapy of melanoma
48. Bioactivity of recombinant human TNF receptor fragments. Cytokines and their receptors—from clonal to clinical investigation
49. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin
50. Selective species specificity of tumor necrosis factor for toxicity in the mouse
51. Human TNF mutants with selective activity on the p55 receptor
52. Effects of ketoprofen on respiratory and circulatory changes in endotoxic shock
53. Coley's vaccine and TNF therapy